Who is GAMETO
Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives. Womens health is a vastly underserved therapeutic are...
Read More
-
Headquarters: New York, New York, United States
-
Date Founded: 2020
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Gameto
Answer: Gameto's headquarters are located at New York, United States
Answer: Gameto's official website is https://gametogen.com
Answer: Gameto's revenue is $10 Million to $25 Million
Answer: Gameto's SIC: 2836
Answer: Gameto's NAICS: 541714
Answer: Gameto has 11-50 employees
Answer: Gameto is in Biotechnology
Answer: Gameto contact info: Phone number: Website: https://gametogen.com
Answer: Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives. Womens health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. We aim to change that. Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, we have developed a platform to produce female reproductive cell lines. We use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Our team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Our first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month